Tag: MPH

Funding Support and Acknowledgements: COPDGene: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung,…

Introduction Currently, the emergence of bacterial resistance poses a significant challenge to public health worldwide. With the widespread use of antimicrobial agents in recent years, the isolation of multidrug-resistant Escherichia coli has increased yearly, particularly among Extended Spectrum β-lactamases (ESBLs) producing strains, which can cause not only multi-site infections but…

Japanese motorcycle company Kawasaki has rode into the electric mobility space with three new models – sadly not the Ninja BEV previewed at last year’s EICMA expo, but with the launch of the Noslisu series electric tilting three-wheelers on its home turf. According to a press release issued by Kawasaki…

New data presented at ASCO Annual Meeting 2023 suggest racial disparities may lead to increased risk of second primary malignancies (SPMs) among patients with diffuse large B-cell lymphoma (DLBCL) in the United States. Researchers explored a large-scale population-based database and found substantial disparities in SPM risk by race/ethnicity. Pragati Advani…

Credit: Pixabay/CC0 Public Domain Researchers who lead the world’s first comprehensive sequencing program for newborn infants have published the next chapter in the ongoing study of the BabySeq Project, with new findings on infants and families who have been followed for three to five years. In a study published in…

Introduction Escherichia coli, a member of the Enterobacterales family, is a common opportunistic pathogen that can cause various infectious illnesses, including urinary tract infections (UTIs) and other infections acquired in the community.1,2 The presence of carbapenemases in E. coli poses a serious threat to public health. These carbapenemase genes may…

Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology. Patients with depression had the lowest survival,…

Given the shortcomings of conventional biopsy, liquid biopsy offers a different strategy as a cutting-edge diagnostic tool.1 By examining the circulating blood components, it is possible to assess the limiting factors more accurately for better treatment choices—clonal variations and heterogeneity. Additionally, liquid biopsy provides a more accurate representation of the…

Pathalys and LaunchTx leverage recently announced collaboration to accelerate enrollment for the upacicalcet development program. RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 31, 2023 /PRNewswire/ — Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx), a clinical development company, today announced…

Qian Wang, MD, MPH, assistant professor at Case Western Reserve University, thoracic oncologist at University Hospital Siteman Cancer Center, discusses the relevant metrics to determine the risk factor of developing small cell lung cancer (SCLC). SCLC accounts for about 50% of all cases of lung cancer, with smoking being the…

A new study published in the peer-reviewed OMICS: A Journal of Integrative Biology identified genes for virulence and antimicrobial resistance in two bacteria that co-occur with C. difficile, suggesting these pathogens as emerging potential threats in planetary health. Thokur Sreepathy Murali, PhD, Ankit Singh Tanwar, Padival Shruptha and colleagues from…

Newswise — Boston – Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the…

Ferring’s clinical development partner, Seikagaku Corporation, plans to proceed with preparation for a Biologics License Application to the U.S. Food and Drug Administration. PARSIPPANY, N.J., May 26, 2023–(BUSINESS WIRE)–Ferring Pharmaceuticals (Ferring) announced that its clinical development partner, Seikagaku Corporation (Seikagaku), achieved positive topline results for its registrational Phase 3 clinical…

PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH),…

In the United States (US), The U.S. Preventive Services Task Force (USPSTF) continues to push forth recommendations to stop diseases like skin cancer from developing. However, skin cancer still impacts approximately 9,500 Americans each year, according to the American Academy of Dermatology. According to Meredith McKean, MD, MPH, the USPSTF…

Image Credit: © SciePro [stock.adove.com] Treatment with roxadustat (FG-4592) demonstrated noninferiority vs recombinant erythropoietin alfa (Sepo) regarding the primary end point of change in hemoglobin level from baseline to an average level during weeks 9 to 13 for the treatment of anemia in Chinese patients receiving concurrent chemotherapy for non-myeloid…

Positive results were announced from a phase 3 trial evaluating a next-generation, low-dose copper intrauterine device (IUD) for the prevention of pregnancy. The Copper 175mm2 IUD was investigated in a single-arm, open-label study (ClinicalTrials.gov Identifier: NCT03633799) that included women aged 17 through 45 years (60.1 % nulliparous and 39.9% parous)….

Roxadustat proved to be noninferior to recombinant erythropoietin alfa (Sepo) with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial (NCT05301517).1…

If approved by the U.S. Food and Drug Administration, this newly designed, low-dose copper IUD could be the first hormone-free IUD in almost 40 years ROSWELL, Ga., May 18, 2023 /PRNewswire/ — Sebela Women’s Health Inc., a part of Sebela Pharmaceuticals, today announced positive results of a Phase 3 study…

Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa Plan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. today announced positive topline data from Company’s…

Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa Plan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. today announced positive topline data from Company’s…

Introduction Multidrug-resistant Enterobacteriaceae infection is a severe threat to public health that is worsening globally and is associated with increasing mortality rates.1 Klebsiella pneumoniae is a significant pathogen that contributes to the dissemination of multidrug-resistant strains in healthcare environments.2 K. michiganensis is a novel specie of pathogenic Klebsiella genus. Since…

In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, of Columbia University Herbert Irving Comprehensive Cancer Center, discusses testing guidance for identifying Lynch syndrome. Universal testing with MSI or immunohistochemistry [IHC] in all newly diagnosed colorectal cancer [CRC] is a firm guideline, and…

May 15, 2023 — Wherever you look, machine learning applications in artificial intelligence are being deployed to change the status quo. This is especially true in healthcare, where technological advancements are accelerating drug discovery and identifying potential new cures. But this progress does not come without red flags. They also…

Kaggle’s “Taxi Trajectory Data from ECML/PKDD 15: Taxi Trip Time Prediction (II) Competition” is one of the most used mobility / vehicle trajectory datasets in computer science. However, in contrast to other similar datasets, Kaggle’s taxi trajectories are provided in a format that is not readily usable in MovingPandas since…

Babies born in U.S. hospitals currently undergo routine newborn screening, a laboratory test to identify the risk of up to 60 treatable conditions. But hundreds of genetic disorders, including a growing number of devastating childhood diseases, now have targeted treatments, including gene and cell therapies, that can offer permanent cures….

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, today announced that The Lancet Infectious Diseases published detailed results from…

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, today…

Chenxing Wei,1,* Jian Chen,1,* Tanveer Muhammad Anwar,2,* Lingling Huang,1 Wenjie Yang,3 Xueyan Dong,1 Qiong Chen,1 Min Yue,2,4,5 Daojun Yu1,3 1Department of Medical Laboratory, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People’s Republic of China; 2Department of Veterinary Medicine, Institute of Preventive Veterinary Sciences, Zhejiang University…

WALTHAM, Mass., May 11, 2023–(BUSINESS WIRE)–Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, today announced that The Lancet Infectious Diseases published detailed results from the pivotal Phase 3 ATTACK trial of sulbactam-durlobactam, the first pathogen-targeted therapy being…

Findings highlight company’s approach is highly accurate for early-stage (I-II) detection: CRCs (91% sensitivity) and AA (54% sensitivity) at 92% specificity Data offer hope for the future of blood-based early cancer detection CAMBRIDGE, Mass., May 09, 2023–(BUSINESS WIRE)–Headline and first paragraph of release, colorectal cancer sensitivity percent should read: 93%…

The COVID-19 pandemic has brought to light both strengths and gaps within the healthcare system and the preparedness of nations during a public health crisis. From testings to vaccinations, we have witnessed and experienced how the healthcare industry has rallied together to meet the public health needs of communities.  As…

Findings highlight company’s approach is highly accurate for early-stage (I-II) detection: CRCs (91% sensitivity) and AA (54% sensitivity) at 92% specificity Data offer hope for the future of blood-based early cancer detection CAMBRIDGE, Mass.–(BUSINESS WIRE)– Universal Diagnostics (Universal DX), a bioinformatics and multi-omics company on a mission to transform cancer…

Credit: Unsplash/CC0 Public Domain Babies born in U.S. hospitals currently undergo routine newborn screening, a laboratory test to identify the risk of up to 60 treatable conditions. But hundreds of genetic disorders, including a growing number of devastating childhood diseases, now have targeted treatments, including gene and cell therapies, that…

The emergence of an XDR S. sonnei outbreak in the United Kingdom. A cgMLST dendrogram (midpoint rooted) of clinical isolates from the UK (n = 2,820) and genomic subtype references (n = 120) with the scale bar indicating distance in cgMLST alleles. Metadata tracks show patient and genomic features for isolates colored according to…

The U.S. Food and Drug Administration (FDA)–approved diabetes medication Mounjaro (tirzepatide) is one step closer to approval as a treatment for adults with overweight or obesity. In SURMOUNT-2, a second phase 3 clinical trial for chronic weight management, Mounjaro helped people with diabetes lose nearly 16 percent of their body…

Researchers found in their analysis that visual impairment is associated with hallucinations, depression, agitation, and psychosis in patients with dementia, although, aging and comorbidities, among other factors, may be involved. (Image Credit: Adobe Stock/BrilliantPhotos.com) Melissa Li, MD, and Ali Hamedani, MD, MPH, from the University of Pennsylvania Perelman School of…

ORLANDO, Florida — Non-Hispanic persons of African ancestry typically have worse clinical outcomes from colorectal cancer (CRC) than individuals of other heritages, a disparity attributed to many factors, including socioeconomic, environmental, and genetic influences, as well as less access to care. Results from a new genomic study provide greater clarity…

By Marjorie E. Zettler, Ph.D., MPH, executive director of clinical science, Regor Pharmaceuticals, Inc. On April 6, AbbVie announced that it was voluntarily withdrawing ibrutinib from the U.S. market for two indications: mantle cell lymphoma (MCL, for patients who have received at least one prior therapy) and marginal zone lymphoma…

April 13, 2023 3 min read Source/Disclosures Published by: Source: Gao W, et al. Abstract HSR23-118. Presented at: NCCN Annual Conference; March 31-April 2, 2023; Orlando. Disclosures: AbbVie and Genmab sponsored this study. Lahue reports employment with Alkemi and an advisory board role with EvoEndo. Please see…

Finding when and where DNA changes as a disease progresses allows for better treatment of chronic, genetic-based diseases including cancer, diabetes, and neurological and developmental disorders. At the University of Arizona, genome sequencers are used across multiple disciplines. But the newest genome sequencer in the UArizona Health Sciences offers the…

As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells. As reported March 14 in Nature Communications, the researchers found that in addition…

Summary of the human isolates Between January 2014 (when routine WGS was first implemented at the GBRU) and December 2021, 83 isolates from human cases were confirmed as E. albertii. Over this 8-year period, between 4 and 23 isolates were identified per year (Supplementary Fig. 1). Metadata regarding patient gender, age…

Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements over placebo in signs and symptoms of hidradenitis suppurativa at week 16, as measured by HiSCR50 Bimekizumab demonstrated deep levels of clinical response over placebo at week 16, as measured by HiSCR75, a…

Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements over placebo in signs and symptoms of hidradenitis suppurativa at week 16, as measured by HiSCR50 Bimekizumab demonstrated deep levels of clinical response over placebo at week 16, as measured by HiSCR75, a…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer…

Adding enzalutamide (Xtandi) to leuprolide significantly improved metastasis-free survival (MFS) vs leuprolide alone in patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence (BCR), according to topline findings from the phase 3 EMBARK trial (NCT02319837).1 Treatment with the enzalutamide/leuprolide regimen also led to statistically significant improvements in time…

© Reuters. Pfizer Inc. (NYSE:) and Astellas Pharma Inc. today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial…

Treatment with fezolinetant, an investigational oral, nonhormonal selective neurokinin-3 (NK3) receptor antagonist being studied for the treatment of moderate to severe menopause-related vasomotor symptoms (VMS), resulted in statistically significant reductions in the frequency and severity of VMS in a pivotal phase 3 trial, according to an announcement from Astellas Pharma,…

Adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) significantly improved time to prostate-specific antigen (PSA) progression (TTPP) versus ADT alone in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC), meeting the primary end point of the phase 3 China ARCHES study (NCT04076059).1 Astellas Pharma plans to submit the data from…

Enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) produced a statistically significant improvement in time to prostate-specific antigen (PSA) progression compared with ADT and placebo in men with metastatic hormone-sensitive prostate cancer (mHSPC), meeting the primary end point of the phase 3 China ARCHES study (NCT04076059).1 Results also showed that the…

Today, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of the safety and efficacy of Pfizer’s respiratory syncytial virus (RSV) vaccine candidate. If the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) abide by this recommendation, the vaccine, Abrysvo (RSVpreF),…

This interview segment with HCPLive featured Evan S. Dellon, MD, MPH, during which he describes treatment of eosinophilic esophagitis (EoE) and some limitations of his team’s recent study. Dellon is known for his work as both professor of medicine and adjunct professor of epidemiology at University of North Carolina School…

A new HCPLive interview featured a discussion with Evan S. Dellon, MD, MPH, during which he discussed trial data showing that eosinophilic esophagitis (EoE) patients treated with dupilumab had high rates of allergic/atopic comorbidities.1 He serves as a professor of medicine and as adjunct professor of epidemiology at the Center…

A long-acting injectable regimen of cabotegravir and rilpivirine ([CAB+RPV LA] Cavenuva; ViiV Healthcare) may be as effective as traditional, once-daily bictegravir, emtricitabine, and tenofovir alafenamide ([BIC/FTC/TAF] Biktarvy; Gilead) for patients with HIV, according to the results of a study by ViiV Healthcare that was presented at the 30th Conference on…

Entry EC 1.7.1.4                  Enzyme                                  Name nitrite reductase [NAD(P)H];nitrite reductase (reduced nicotinamide adenine dinucleotide (phosphate));assimilatory nitrite reductase (ambiguous);nitrite reductase [NAD(P)H2];NAD(P)H2:nitrite oxidoreductase;nit-6 (gene name) Class Oxidoreductases;Acting on other nitrogenous compounds as donors;With NAD+ or NADP+ as acceptorBRITE hierarchy Sysname ammonia:NAD(P)+ oxidoreductase Reaction(IUBMB) NH3 + 3 NAD(P)+ + 2 H2O = nitrite + 3 NAD(P)H…

Credit: CC0 Public Domain Type 2 diabetes is a chronic disease in which the body does not produce enough of the hormone insulin, which regulates blood sugar, while cells in the muscle, fat and digestive system simultaneously become less sensitive to it, absorbing less sugar from the blood stream. The…

–  Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical events –  Lambda reduced risk of hospitalization or emergency room visits by 51% (primary endpoint) –  Lambda reduced risk of hospitalization by 42%…

Isolation, phenotypic identification, pathogenicity and antibiogram profiling Enterococcus faecalis strains BFF1B1, BFFF11 and BFPS6 were cultured in Streptococcus selective agar media (Himedia, India). The culture characteristics such as colony, morphological, physiological and biochemical characteristics of these strains BFF1B1, BFFF11 and BFPS6 were summarized in the Supplementary Table S1. All of…

Antimicrobial susceptibility data of S. sonnei in France Our review of S. sonnei antimicrobial susceptibility data obtained between 2005 and 2021 (based on 7121 isolates received and confirmed at the French National Reference Center for E. coli, Shigella and Salmonella, FNRC-ESS, Institut Pasteur) revealed a sharp increase in the percentage…

Based on the results of the phase 3 SPOTLIGHT trial, zolbetuximab (Astellas Pharma), an investigational first-in-class Claudin 18.2 (CLDN18.2) targeted monoclonal antibody, and mFOLFOX6, a combination regimen of oxaliplatin, leucovorin, and fluorouracil, were found to increase progression-free survival (PFS) in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric…

COPDGene Phase 3: Grant Support and Disclaimer: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National…

by Leigh MacMillan Ondansetron is commonly used in children and adults to prevent postoperative nausea and vomiting (PONV). Variation in the gene for the metabolic enzyme CYP2D6 can affect response to ondansetron, and it is recommended that alternative anti-emetic therapy be considered for adults who are ultrarapid metabolizers. However, data…

A blood-based multicancer early detection (MCED) test using cell-free DNA (cfDNA) is feasible for outpatients and has a positive predictive value of about 40%, according to a study presented at the 2022 annual meeting of the European Society for Medical Oncology. Deb Schrag, MD, MPH, and colleagues examined the clinical…

Patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma may derive benefit from MT-101, which was granted fast track designation by the FDA. The FDA has granted fast track designation to MT-101 for the treatment of patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma (PTCL), according to a press release from Myeloid Therapeutics….

Financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic license applications (BLA) Phase 2 data for izokibep in PsA presented at the 2022 European Alliance of Associations for Rheumatology Congress (EULAR) demonstrated differentiated efficacy across multiple endpoints – including…

Responsibilities Requisition # HRC0992682 The newly formed Precision Biomarkers Laboratories (PBL) at Cedars-Sinai is seeking a highly skilled bioinformatics professional with an expertise in statistical methods and data applications. This role will be responsible for developing robust statistical measures to evaluate, analyze, and integrate proteomics data for continuous quality control…

Three doctors have filed a complaint against social media company Twitter, which suspended their accounts on the grounds that they had posted misleading information about COVID-19 vaccines. On behalf of the three physicians, their attorneys filed the complaint on June 26 against the social media company for permanently suspending their…

Introduction Escherichia coli is a common Gram-negative opportunistic pathogen that causes invasive host infections through virulence factors such as flagella, toxin secretion, and adhesins. According to the source of the infection, pathogenic E. coli can be classified as intestinal (diarrheagenic) and extraintestinal (ExPEC). Uropathogenic E. coli (UPEC) is the most…

Earlier this month, a type of short-haired cattle, called PRLR-SLICK, was added to a very short list of animals given a low-risk assessment by the FDA’s Center for Veterinary Medicine (CVM). What’s so special about these cattle is that they are the first intentional genomic alteration (IGA) in an animal…

September 17, 2021 2 min read Source/Disclosures Published by: Disclosures: The authors report no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email…

Hao Wu, PhD, an assistant professor of Genetics in the Perelman School of Medicine at the University of Pennsylvania PHILADELPHIA— The National Institutes of Health (NIH) has selected Penn Medicine as one of 25 award recipients across 30 sites in the United States to serve as Impact of Genomic Variation…

Entry EC 1.14.12.17               Enzyme                                  Name nitric oxide dioxygenase Class Oxidoreductases;Acting on paired donors, with incorporation or reduction of molecular oxygen;With NADH or NADPH as one donor, and incorporation of two atoms of oxygen into the other donorBRITE hierarchy Sysname nitric oxide,NAD(P)H:oxygen oxidoreductase Reaction(IUBMB) 2 nitric oxide + 2 O2 + NAD(P)H =…

DALLAS, Sept. 2, 2021 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company’s clinical…

Introduction Nuclear protein in testis (NUT) carcinoma (NC) is defined by the rearrangement of the chromosomal region 15q14 harboring the NUTM1 gene. As a clinically aggressive neoplasm with poor differentiation, NC was previously believed to occur primarily in children and young adolescents. However, with an increasing number of reports, middle-aged…